MCR Therapeutics will develop peptides to stimulate the production of melanin, a pigment which shields humans against ultraviolet rays and skin cancer.
University of Arizona has granted two licences for therapeutic peptides for skin cancer to US-based MCR Therapeutics, which has raised an undisclosed sum from Tech Launch Arizona (TLA), the university’s tech transfer arm.
TLA provided the funding through its Asset Development Program, which finances feasibility and proof-of-concept studies for early-stage projects. MCR has also received a grant of undisclosed size from government-owned research agency National Science Foundation’s NSF Innovation Corps program.
MCR is developing peptides that are expected to aid…
